Greater antitumor efficacy of paclitaxel administered before epirubicin in a mouse mammary carcinoma

Anna Cividalli, Giorgio Cruciani, Esther Livdi, Eugenia Cordelli, Brighitta Eletti, Donatella Tirindelli Danesi

Research output: Contribution to journalArticle

9 Citations (Scopus)


Combined treatment with paclitaxel and anthracyclines is increasingly being tested in clinical practice. Epirubicin is in general administered before paclitaxel. We have investigated, using a murine mammary adenocarcinoma, whether the efficacy and toxicity of this combination is influenced by treatment sequence, different time intervals and dose intensity. The tumor was transplanted into the right hind foot of C3D2F1 female mice. Paclitaxel was administered i.p. in doses ranging from 15 mg/kg to 75 mg/kg and epirubicin (i.p. or i.v.) in doses from 9 mg/kg to 30 mg/kg. The hepatic and peritoneal toxicity observed with epirubicin administration increased in combined treatments (stronger with i.p. than i.v. epirubicin administrations) and was dose-dependent. When paclitaxel and epirubicin were administered simultaneously or paclitaxel was given 24 h before epirubicin, the same tumor growth delays were obtained in all groups. A smaller effect was observed when paclitaxel was administered 24 h after epirubicin. Increasing the epirubicin or paclitaxel dose led to higher tumor growth delays but also an increased toxicity. In conclusion, in this experimental model, the administration of 45 mg/kg paclitaxel before 15 mg/kg epirubicin was very effective and the increased toxicity can be limited by introducing an interval of 24 h between drug administrations. These results should be considered when designing clinical trials.
Original languageEnglish
Pages (from-to)236 - 244
Number of pages9
JournalJournal of Cancer Research and Clinical Oncology
Issue number5
Publication statusPublished - 1998
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this